Rapid Antidepressant Effects of ATP and Phosphocreatine
NCT ID: NCT03138681
Last Updated: 2017-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
42 participants
INTERVENTIONAL
2017-05-03
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
NCT05792540
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
NCT01052077
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
NCT01808612
A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
NCT03374475
Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder
NCT01119430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
placebo is given intravenously twice a day for 14 days
ATP
ATP
ATP (100mg) is given intravenously twice a day for 14 days
phosphocreatine
Phosphocreatine
Phosphocreatine (1g) is given intravenously twice a day for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
placebo is given intravenously twice a day for 14 days
ATP
ATP (100mg) is given intravenously twice a day for 14 days
Phosphocreatine
Phosphocreatine (1g) is given intravenously twice a day for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Major depressive disorder diagnosed by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
* Hamilton depression rating scale score \>= 20 at screening
* Written informed consent
Exclusion Criteria
* Suicidal idea or action that requires hospitalization
* Post Traumatic Stress Syndrome in recent 6 months
* Secondary depression, or have a direct familial history of schizophrenia
* Diseases that prevent from appropriate expression of depressive emotion
* Psychiatric disorders including bipolar disorder and schizophrenia
* Severe heart, kidney, lung or liver diseases that require hospitalization
* Diabetes
* Neurologic disease (eg., epilepsy, infarct, multiple sclerosis, brain tumor)
* Inflammatory disease including autoimmune disease
* Taking anti-inflammatory medication
* Taking antiarrhythmic drugs, antidiabetic agents or tryptophan
* Substance abuse or dependence history in recent 6 months
* Pregnant or having plan to be pregnant
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhujiang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhujiang Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chen Y, Cao X, Zang W, Tan S, Ou CQ, Shen X, Gao T, Zhao L. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study. Trials. 2019 Jan 9;20(1):34. doi: 10.1186/s13063-018-3115-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-SJNK-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.